_the-mechanism-of-action-of-car-t-preview-1.jpg "The Mechanism of Action of CAR T from yescarta car t cell therapy Video Screenshot Preview 1")
Gallery_the-mechanism-of-action-of-car-t-preview-3.jpg "The Mechanism of Action of CAR T from yescarta car t cell therapy Video Screenshot Preview 3")
Gallery_the-mechanism-of-action-of-car-t-preview-hqdefault.jpg "The Mechanism of Action of CAR T from yescarta car t cell therapy Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 2 minutes 40 seconds
👁 View: 3.7K times
Play Audio:👁 View: 3.7K times
Description:
Kite Pharma
Kite Pharma
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_panel-how-will-the-way-people-processes-and-technologies-interact-change-in-the-next-ten-years.webp "Discussing some of the forces and factors that are changing the way we operatenDebating how these influences will continue to evolve, and how they will shape our organizationsnTechnological progress is a given, but will there also be fundamental changes to our people and our processes in the next decade, or should we expect incremental modifications rather than a sea change?nThinking about Risk Management: How should we brace ourselves for the unexpected in a global business environment whose on")
⏲ 25 min 82 sec ✓ 25-May-2023
_expert-explains-potential-long-term-impact-of-yescarta-car-t-cell-therapy-for-patients-with-lymphoma.webp "curetoday")
Expert Explains Potential Long-term Impact of Yescarta CAR-T Cell Therapy For Patients with Lymphoma
⏲ 1 minute 51 seconds 👁 499
_novel-cell-type-therapeutic-platforms-in-oncology-part-ii-a-cell-by-any-other-name-does-not-work-the-same.webp "Moderator:nJoel Sandler, PhD, Principal and Practice HeadnnPanelists:nDebora Barton, MD, CMO, Carisma TherapeuticsnCharles Nicolette, PhD, CEO, CoImmune Inc.nKimberly Noonan, PhD, MPH, EVP, CSO and Founder, WindMIL TherapeuticsnnPerhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry, investor, and oncologist communities alike. A fundamental but often vaguely understood component of emerging cell therapy platforms is the")
⏲ 44 min 7 sec ✓ 10-Mar-2022
_car-t-cell-therapy-explained-manufacturing-process-amp-how-it-works.webp "Henrik's Lab")
_inside-the-lab-car-t-cell-therapy-explained-124-city-of-hope.webp "City of Hope")
_davids-car-t-cell-therapy-experience.webp "Kite Pharma")
_panel-how-will-the-way-people-processes-and-technologies-interact-change-in-the-next-ten-years.jpg)
_expert-explains-potential-long-term-impact-of-yescarta-car-t-cell-therapy-for-patients-with-lymphoma.jpg)
_novel-cell-type-therapeutic-platforms-in-oncology-part-ii-a-cell-by-any-other-name-does-not-work-the-same.jpg)
_car-t-cell-therapy-explained-manufacturing-process-amp-how-it-works.jpg)
_inside-the-lab-car-t-cell-therapy-explained-124-city-of-hope.jpg)
_davids-car-t-cell-therapy-experience.jpg)
![[+]](/images/menu.gif){kind=small}